Henlius

Shanghai Henlius Biotech, Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the research, development, and commercialization of biologics aimed at treating oncology and autoimmune diseases. Founded in 2010, the company has developed several products, including HLX01, a monoclonal antibody biosimilar for treating non-Hodgkin lymphoma. Currently, it has two products under new drug application review and one product under European Medicines Agency review, alongside approximately 20 clinical studies involving 10 products and 8 combination therapies. Henlius is also collaborating with other firms to develop treatments for COVID-19 and eye diseases, such as wet age-related macular degeneration. As a subsidiary of Shanghai Fosun Pharmaceutical, the company is committed to providing innovative and affordable biologics for patients both in China and internationally.